ABVC BioPharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ABVC BioPharma, Inc. on May 25, 2022, regarding events occurring on May 20, 2022. The filing discloses the results of the Company's 2022 Annual Meeting of Shareholders. A quorum was established with 16,239,330 shares (53.58% of voting power) represented by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
All five proposals submitted to shareholders were approved. The specific results were as follows:
- Proposal 1 (Re-election of 8 Directors): All nominees were re-elected. Notably, Yoshinobu Odaira received 380,984 withheld votes, while other nominees received between 5,342 and 5,942 withheld votes.
- Proposal 2 (Election of 3 New Directors): Che Wei Hsu, Shuling Jiang, and Kuang-Tseng Chen were elected. Shuling Jiang received 417,000 withheld votes.
- Proposal 3 (Ratification of Auditors): KCCW Accountancy Corp. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 16,211,242 votes in favor.
- Proposal 4 (Say-on-Pay): The advisory vote on executive compensation was approved with 14,959,253 votes in favor.
- Proposal 5 (Say-on-Pay Frequency): Shareholders voted to hold say-on-pay votes every three years (14,543,446 votes), rather than annually or every two years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the 53.58% participation rate.
- Review the proxy statement for details on the significant number of withheld votes for directors Yoshinobu Odaira and Shuling Jiang.
- Confirm the Company's decision to reduce the frequency of say-on-pay votes to every three years.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.